Semaglutide in Cystic Fibrosis-Related Diabetes.

Like Comment
In spite of the evidence that inadequately controlled glycemia is associated with worse clinical outcomes, CFRD is not well controlled in a majority of patients. The objective of this report is to demonstrate the effect of the addition of semaglutide, a GLP-1RA, to basal insulin to control glycemia in one such patient.The replacement of rapidly acting prandial insulin with semaglutide weekly with continuation of basal insulin. HbA1c was measured and continuous glucose monitoring was conducted.There was a significant improvement in glycemic control, reduction in HbA1c from 9.1% to 6.7% and stable euglycemic pattern on CGM (mean glucose: 142 mg/dL and SD of 51) within 3 month of starting treatment. There was no increase in plasma pancreatic enzyme concentrations.Semaglutide at a small dose was able to replace prandial insulin and control glycemia to perfection in combination with basal insulin.


Click here to read the full article @ The Journal of clinical endocrinology and metabolism

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
3882 Contributions
1 Followers
0 Following

No comments yet.